M&A Deal Summary

Genmab Acquires Merus

On September 29, 2025, Genmab acquired life science company Merus for 8.0B USD

Acquisition Highlights
  • This is Genmab’s 2nd transaction in the Life Science sector.
  • This is Genmab’s largest (disclosed) transaction.
  • This is Genmab’s 1st transaction in the Netherlands.

M&A Deal Summary

Date 2025-09-29
Target Merus
Sector Life Science
Buyer(s) Genmab
Deal Type Add-on Acquisition
Deal Value 8.0B USD
Advisor(s) Jefferies (Financial)
Latham & Watkins
NautaDutilh (Legal)

Target

Merus

Utrecht, Netherlands
Merus BV is a fully-integrated biotechnology company developing cancer therapeutics that combine the benefits of monoclonal antibodies with the ability of simultaneously addressing multiple targets. Merus was founded in 2003 and is based in Utercht, Netherlands.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Genmab

Copenhagen, Denmark

Category Company
Founded 1999
Sector Life Science
Employees2,639
Revenue 3.0B USD (2024)
DESCRIPTION

Genmab is an international biotechnology company using its antibody technology platform to offer bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function-enhanced antibodies, and antibody-drug conjugates. Genmab was formed in 1999 and is headquartered in Copenhagen, Denmark.


DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
Country: Netherlands M&A 1 of 1
Year: 2025 M&A 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-04-03 ProfoundBio

Seattle, Washington, United States

ProfoundBio is a clinical-stage biotechnology company developing next-generation ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer and other FRα-expressing solid tumors. ProfoundBio is based in Seattle, Washington.

Buy $1.8B